This study is a sub-set of a wider research program seeking to understand the barriers and enablers to the introduction of a heat-stable, inhaled formulation of oxytocin for the prevention of PPH in resource-limited settings. This evidence concerns the gene OXT and pulmonary arterial hypertension.